◀ Back to IL2

FASLG — IL2

Text-mined interactions from Literome

Dai et al., J Immunol 1999 : IL-2 up-regulated Fas ligand (FasL) and down-regulated gamma c expression on activated 2C cells in vitro and in vivo
Xiao et al., Eur J Immunol 1999 : FasL promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and Egr-3 ... The data suggests that the GGGCGGAAA site present in the 5 ' end of the minimal FasL promoter is critical to IL-2 induced FasL gene activation ... In contrast, mutation at the Egr site had no effect on IL-2 induced FasL promoter activity
Blüher et al., Eur J Endocrinol 1999 (Thyroiditis, Autoimmune) : However, in contrast to results of recent in vitro studies, in the BB/W rat Fas/FasL expression is not regulated by IL-2 , -4, -6, -10, -12, interferon gamma, and tumor necrosis factor alpha
Demir et al., Anticancer Res 1999 (Bone Neoplasms...) : We designed a prospective pilot study to evaluate in vivo effects of low dose IL-2 and IFN-alpha combination on expression of Bcl-2, FAS ( Apo-1/CD 95 ), Fas Ligand , IL-2 receptor ( CD25 ), and HLA-DR on peripheral lymphocytes in patients with advanced renal cell carcinoma
Nguyen et al., Immunology 2001 : Interleukin-2 (IL-2) , an enhancer of AICD, can also enhance FasL expression
Frucht et al., Genes Immun 2001 (Severe Combined Immunodeficiency) : Activated T cells in these patients failed to express Fas ligand (FasL) in response to IL-2 , which may explain the accumulation of T cells with an activated phenotype and a skewed T cell receptor ( TcR ) Vbeta family distribution
Duan et al., Clin Cancer Res 2004 (Osteosarcoma) : The purpose of these studies was to determine whether alkylating agents affect the expression of Fas ligand (FasL) and whether interleukin 12 enhances the sensitivity of human OS cells to alkylating agents
Mauz-Körholz et al., Immunol Invest 2004 : Regulation of interleukin-2 induced soluble Fas ligand release from human peripheral blood mononuclear cells ... We therefore investigated the regulation of IL-2 induced release of soluble Fas Ligand ( sFasL ), since this factor is known to possess anti-tumor activities
Gordon et al., J Immunol 2005 (Asthma...) : Splenic CD8alpha+ dendritic cells reportedly tolerize T cell responses by inducing Fas ligand mediated apoptosis, suppressing IL-2 expression, or catabolizing T cell tryptophan reserves through expression of IDO
Zhu et al., Transplant Proc 2008 : The costimulatory blockade down-regulated the expression of 2 Th1 cytokines ( interferon-gamma [ IFN-gamma ] and interleukin-2 [ IL-2 ] ) and 2 Th2 cytokines ( IL-4 and IL-10 ), reduced the numbers of graft infiltrating CD4+ and CD8+ lymphocytes, and inhibited the expression of both perforin/GrB and FasL in allografts
Makrigiannis et al., J Immunol 1997 : Since RAP is known to block IL-2 signaling through the IL-2R, we hypothesized that RAP may interfere with CTL generation by inhibiting IL-2 induced expression of granzyme (Gzm) B, perforin, and/or Fas ligand (FasL)
Kawakami et al., J Lab Clin Med 1998 : Although only minimal FasL expression was detected on unstimulated PBLs, FasL expression was markedly induced by IL-2 or PMA plus ionomycin, suggesting that Fas and FasL were both expressed on IL-2 stimulated or PMA-plus-ionomycin stimulated PBLs
Ayroldi et al., Blood 1998 : The results indicated that transcription of Fas/FasL is controlled by interleukin-2 (IL-2) production and that CD2 triggering rescues a T-cell hybridoma from AICD via decreased production of IL-2
Desbarats et al., Nat Med 1998 : In vitro, FasL engagement inhibited CD4+ T-cell proliferation, cell-cycle progression, and IL-2 secretion
Williams et al., J Immunol 1998 : TCR stimulated expression of functional Fas ligand was attenuated in a stereospecific manner by NOS inhibitors, but these compounds did not inhibit TCR stimulated IL-2 secretion or CD69 surface expression